FORMULATION DEVELOPMENT AND EVALUATION OF TEMOZOLOMIDE LOADED HYDROGENATED SOYA PHOSPHATIDYLCHOLINE LIPOSOMES FOR THE TREATMENT OF BRAIN CANCER
Abstract
Objective: The objective of this study was to encapsulate temozolomide (TMZ) in the liposomal formulation for the treatment of glioblastoma. TMZ
is one of the most effective substances in vitro against cells derived from glioblastoma. However, it may not have a significant effect in vivo due to
poor penetration in brain which may be attributed to the blood-brain-barrier. The main objective of this investigation is to develop a liposomal drug
delivery system which could improve the brain targeting, and solve the treatment-related problems.
Methods: In this study, TMZ loaded liposomes were prepared by ethanol injection method. The characterization of formulated liposomes was carried
out by vesicle size, entrapment efficiency, surface morphology, and in vitro drug release study. The prepared liposomes were also evaluated for cell
uptake and cell cytotoxicity studies.
Results: Particle size and entrapment efficiency were found to be 105.7±3.9 nm and 78.25±0.98%, respectively. 75% of the entrapped drug was
released in 24 hrs from the selected liposomal formulation. Cell uptake study reveals that hydrogenated soya phosphatidylcholine (HSPC) loaded TMZ
liposomes interact with the glioblastoma cells and kill the cancer cells effectively. Cytotoxicity assay confirms that drug loaded HSPC liposomes are
more efficient with respect to killing of glioblastoma cells as compared to plain drug.
Conclusion: These results suggest that the TMZ loaded HSPC liposome may serve as a proficient targeted drug delivery system for the effective
management of glioblastoma.
Keywords: Temozolomide, Liposomes, Hydrogenated soya phosphatidylcholine, Cholesterol, Glioblastoma.
Downloads
References
Béduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors
using nanocarriers. Biomaterials 2007;28(33):4947-67.
Pardridge WM. Blood-brain barrier delivery. Drug Discov Today
;12(1-2):54-61.
Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier:
Development, composition and regulation. Vascul Pharmacol
;38(6):323-37.
Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the
treatment of malignancies. Expert Opin Drug Saf 2009;8(4):493-9.
Fauchon F, Chiras J, Poisson M, Rose M, Terrier L, Bories J, et al.
Intra-arterial chemotherapy by cisplatin and cytarabine after temporary
disruption of the blood-brain barrier for the treatment of malignant
gliomas in adults. J Neuroradiol 1986;13(3):151-62.
Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for
therapeutic purposes: Osmotic opening and other means. Neurosurgery
;42(5):1083-99.
Lambert DM. Rationale and applications of lipids as prodrug carriers.
Eur J Pharm Sci 2000;11 Suppl 2:S15-27.
Bodor N, Buchwald P. Recent advances in the brain targeting of
neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv
Rev 1999;36(3):229-54.
Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small
molecules using immunoliposomes. Proc Natl Acad Sci U S A
;93(24):14164-9.
Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid
nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev
;59(6):454-77.
Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric
nanoparticles for the drug delivery to the central nervous system.
Expert Opin Drug Deliv 2008;5(2):155-74.
Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M,
et al. Neovascular targeting therapy: Paclitaxel encapsulated in
cationic liposomes improves antitumoral efficacy. Clin Cancer Res
;9(6):2335-41.
Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D.
Optimizing liposomes for delivery of chemotherapeutic agents to solid
tumors. Pharmacol Rev 1999;51(4):691-743.
Parmar JJ, Singh DJ, Hegde DD, Lohade AA, Soni PS, Samad A,
et al. Development and evaluation of inhalational liposomal system
of budesonide for better management of asthma. Indian J Pharm Sci
;72(4):442-8.
Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP.
Tumor-targeted liposomes: Doxorubicin-loaded long-circulating
liposomes modified with anti-cancer antibody. J Control Release
;100(1):135-44.
Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. Ethanol
injection method for hydrophilic and lipophilic drug-loaded liposome
preparation. J Liposome Res 2010;20(3):228-43.
Dua JS, Rana AC, Bhandari AK. Liposome: Methods of preparation
and applications. Int J Pharm Stud Res 2012;3:14-20.
Maruyama K. Intracellular targeting delivery of liposomal drugs to solid
tumors based on EPR effects. Adv Drug Deliv Rev 2011;63(3):161-9.
Torchilin V. Tumor delivery of macromolecular drugs based on the EPR
effect. Adv Drug Deliv Rev 2011;63(3):131-5.
Stockert JC, Blázquez-Castro A, Cañete M, Horobin RW, Villanueva A.
MTT assay for cell viability: Intracellular localization of the formazan
product is in lipid droplets. Acta Histochem 2012;114(8):785-96.
Parikh R, Dalwadi S, Aboti P, Patel L. Inhaled microparticles of
antitubercular antibiotic for in vitro and in vivo alveolar macrophage
targeting and activation of phagocytosis. J Antibiot (Tokyo)
;67(5):387-94.
Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A.
Intracellular uptake and intracavitary targeting of folate-conjugated
liposomes in a mouse lymphoma model with up-regulated folate
receptors. Mol Cancer Ther 2006;5(4):818-24.
Steichen SD, Caldorera-Moore M, Peppas NA. A review of current
AQ4
Asian J Pharm Clin Res, Vol 9, Issue 3, 2016, 340-344
Patel and Parikh
nanoparticle and targeting moieties for the delivery of cancer
therapeutics. Eur J Pharm Sci 2013;48(3):416-27.
Patel BK, Parikh RH, Aboti PS. Development of oral sustained release
rifampicin loaded chitosan nanoparticles by design of experiment.
J Drug Deliv 2013;2013:370938.
???
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.